Medmira (TSE:MIR) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Medmira Inc. has successfully launched its FDA-approved Reveal G4 Rapid HIV 1/2 test, expanded its distribution network, and secured significant new clients in Q3 FY2024. In addition, the company has received funding for clinical trials in Canada for its Complete Syphilis test. Despite these developments, Medmira experienced a decline in revenue and gross profit compared to the previous quarter and recorded a net loss.
For further insights into TSE:MIR stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue